terbinafine HCL
/ Generic mfg.
- LARVOL DELTA
Home
Next
Prev
1 to 25
Of
958
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
July 15, 2025
In vitro effects of the new antifungal compound manogepix (APX001) against the three most clinically relevant species of Sporothrix.
(PubMed, Braz J Microbiol)
- "Fosmanogepix, a prodrug converted into manogepix within the host, has demonstrated broad-spectrum antifungal activity, including other thermodimorphic fungal species...Furthermore, manogepix demonstrated a lower geometric mean of MIC values compared to the antifungal drugs and indifferent interactions with itraconazole, terbinafine and amphotericin B. Prolonged exposure to subinhibitory manogepix concentrations did not induce resistance in the tested strains. These findings indicate manogepix as a promising candidate for the treatment of sporotrichosis, offering a potential alternative in cases of resistance or treatment failure with current antifungals. Further studies are needed to confirm this activity in clinical settings, particularly in diverse geographic regions and against a broader range of Sporothrix strains."
Journal • Preclinical • Dermatology
July 14, 2025
Epidermophyton floccosum, an etiological agent of tinea pedis and tinea unguium: about two cases.
(PubMed, Pan Afr Med J)
- "The patient was treated with terbinafine ointment and short-term antibiotic therapy with favorable clinical course...Conventional techniques are, in most cases, sufficient for diagnosing superficial mycosis. However, identification is sometimes difficult, hence the importance of the contribution of molecular biology in the diagnosis."
Journal • Dermatology • Diabetes • Infectious Disease • Metabolic Disorders
July 03, 2025
Public-health implications of market drug withdrawals: A focus on antifungals for tinea capitis.
(PubMed, J Eur Acad Dermatol Venereol)
- No abstract available
Journal • Dermatology
July 02, 2025
Population Pharmacokinetics of Terbinafine in Children With Tinea Capitis
(clinicaltrials.gov)
- P=N/A | N=60 | Recruiting | Sponsor: Shandong University
New trial • Dermatology
July 02, 2025
Virulence and biological characteristics of Talaromyces wortmannii isolated from deep-seated dermatomycosis by in vitro and in vivo evaluation.
(PubMed, BMC Infect Dis)
- "T. wortmannii can cause human infections. Amphotericin B, itraconazole, posaconazole, and voriconazole may be effective for treatment of such infectoins."
Journal • Preclinical • Dermatology • Infectious Disease
July 01, 2025
Microsporum canis infection from a cat : A source of tinea capitis and dermatophytosis in an entire family
(PubMed, Dermatologie (Heidelb))
- "The patient and his family were successfully treated with terbinafine, and the family cat was treated by a veterinarian. This case underscores the importance of thorough diagnostic procedures, including consideration of pet and familial exposure, to prevent misdiagnosis, reduce the transmission of tinea capitis to other family members and ensure successful treatment outcomes."
Journal • Dermatitis • Dermatology • Immunology • Infectious Disease • Psoriasis • Seborrheic Dermatitis
June 22, 2025
Epidemiological Cutoff Values and Phylogenetic Analysis for Phialophora verrucosa Species Complex, an Agent of Chromoblastomycosis
(ASM Microbe 2025)
- "AFST was performed by broth microdilution method (CLSI M38 Standard) for itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, terbinafine, flucytosine, and amphotericin B. The ECV was established using the iterative statistical method with ECOFFinder v2.1 following CLSI M57 guidelines. These proposed ECVs and MIC distributions, obtained through a multicenter international effort, provide baseline data for P. verrucosa species complex to monitor for antifungal resistance trends. Our phylogenetic tree provides insight into the species complex; MIC distributions can be compared within the complex to pinpoint differences of in vitro susceptibility profiles.*Modal MIC in bold and tentative ECVs gray shaded."
Clinical • Dermatology • Infectious Disease
June 24, 2025
In vitro susceptibility profiles of 16 antifungal drugs against Trichophyton indotineae.
(PubMed, Microbiol Spectr)
- "Luliconazole and amorolfine exhibited low MICs, while itraconazole showed moderately decreased susceptibility, making them preferred treatment options...In contrast, terbinafine, fluconazole, griseofulvin, oteseconazole, isavuconazole, ravuconazole, and amphotericin B exhibited elevated MICs for many strains, with strong correlations between certain azoles, indicating potential cross-resistance. A difference in the susceptibility to terbinafine and voriconazole between Chinese and Indian isolates was observed...Its resistance to first-line antifungal agents, particularly terbinafine and fluconazole, has significantly limited treatment options, emphasizing the urgent need for alternative therapies. This study provides comprehensive antifungal susceptibility data for 16 available antifungal agents, offering valuable insights into potential treatment strategies."
Journal • Preclinical • Dermatology • Infectious Disease
June 26, 2025
EUCAST olorofim MICs for 3,550 Danish mold and dermatophyte isolates from 2020 to 2023.
(PubMed, Antimicrob Agents Chemother)
- "MICs of olorofim, amphotericin B, itraconazole, posaconazole, voriconazole, isavuconazole, and terbinafine were determined using EUCAST E.Def 9.4 and E.Def 11.0 protocols. Olorofim susceptibility was stable over the years and not affected by Cyp51A, Hmg1, or PyrE Q35L alterations. Olorofim maintained broad, potent in vitro activity over the years against a contemporary collection of molds."
Journal • HMGB1
June 22, 2025
Establishment of Epidemiological Cutoff Values Against Fonsecaea monophora, an Agent of Chromoblastomycosis and Cerebral Phaeohyphomycosis
(ASM Microbe 2025)
- "AFST was performed by broth microdilution method (CLSI M38 Standard) for itraconazole, voriconazole, posaconazole, isavuconazole, ketoconazole, terbinafine, flucytosine, and amphotericin B. The ECV was established using the iterative statistical method with ECOFFinder (v2.1) following CLSI M57 guidelines. These proposed ECVs and MIC distributions, obtained through a multicenter international effort, provide baseline data for F. monophora to monitor for antifungal resistance trends. Clinicians and researchers can use these values to help interpret AFST data from this fungus for clinical and public health decision making. *Some labs were unable to perform antifungal susceptibility testing on all antifungals due to inaccessibility to an antifungal or failure to sporulate or grow an isolate."
Clinical • CNS Disorders • Dermatology • Infectious Disease
June 23, 2025
Disseminated Penicillium labradoris (synonym: P. labradorum) in three dogs from Western Australia.
(PubMed, Aust Vet J)
- "Treatment included en bloc metatarsal excision and long-term antifungal therapy, initially with voriconazole and terbinafine, and subsequently delayed-release posaconazole. These cases suggest intriguing aspects of pathogen virulence and potential genetic susceptibility in individual unrelated dogs. Although this fungal species is present in the US, France, and Brazil, it is of great interest that all three Australian cases were from Perth, Western Australia."
Journal • Dermatology • Infectious Disease • Inflammation
June 22, 2025
Validation of a Duplex Real-Time PCR Assay for Rapid Identification of Trichophyton indotineae from Other Dermatophytes
(ASM Microbe 2025)
- "Trichophyton indotineae is an emerging dermatophyte causing outbreaks of extensive tinea infection, often unresponsive to the first-line drug terbinafine...As established by previous investigators1,2 and verified in the present study, the high sequence similarity among members of the TMC necessitates the use of a relative Ct cutoff of 4.4 for specific identification of T. indotineae from other dermatophytes. This T. indotineae molecular assay allows for rapid identification of this emerging drug-resistant dermatophyte."
Dermatology • Infectious Disease
June 22, 2025
Catch Me If You Can
(ASM Microbe 2025)
- "Haemophagocytic lymphohistiocytosis was next diagnosed, necessitating intravenous immunoglobulin and dexamethasone. Voriconazole and terbinafine combination therapy are recommended for first-line treatment. The novel agent olorofim is in late-stage clinical trials and demonstrates good in vitro activity against L. prolificans and has shown promise in patients with L. prolificans infections."
Cognitive Disorders • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Infectious Disease • Leukemia • Musculoskeletal Pain • Myelofibrosis • Oncology • Pain • Rare Diseases
June 22, 2025
When Plants Bite Back!
(ASM Microbe 2025)
- "Management of cutaneous disease involved systemic antifungals in 83% of cases (151/181), and included an azole (116), polyene (28), tetracycline (12), echinocandin (1), and/or terbinafine (1), alone or in combination. Human protothecosis is an uncommon but potentially fatal infection, particularly in immunocompromised persons with disseminated disease. The proportion of cases caused by P. zopfii is higher in disseminated disease than localized disease, although most cases of both poles of the clinical spectra are caused by P. wickerhamii. The case fatality rate of disseminated protothecosis remains unacceptably high."
Dermatology • Human Immunodeficiency Virus • Infectious Disease • Oncology • CD4
June 21, 2025
Uncovering hidden resistance in common dermatophytes through terbinafine era surveillance.
(PubMed, J Eur Acad Dermatol Venereol)
- No abstract available
Journal
June 18, 2025
Clinical isolates of the anthropophilic dermatophyte Trichophyton tonsurans exhibit transcriptional regulation of multidrug efflux transporters that induce antifungal resistance.
(PubMed, Mol Biol Rep)
- "The findings of the study emphasize transcriptional modulation of all transporter genes of T. tonsurans, annotated till date, in response to antifungal challenge, confirming the need to identify multi-drug resistance and select the treatment strategy wisely. It also calls for conducting further sequencing-based studies on T. tonsurans."
Journal • Dermatology
June 18, 2025
Squalene: A High-Value Compound for COVID-19 Vaccine Adjuvants and Beyond Pathways, Production Strategies, and Market Potential.
(PubMed, IUBMB Life)
- "Advanced strategies to enhance squalene yields are explored, including the use of chemical enhancers (methyl jasmonate), antioxidants (alpha-tocopherol), cofactor recycling, and squalene epoxidase inhibitors (terbinafine)...By aligning with Sustainable Development Goals (SDG-3: Good Health and Well-Being), squalene production supports advancements in vaccine development and biotechnological innovations. Future opportunities are highlighted, including novel applications in cancer therapy, functional foods, and anti-aging products, offering pathways to harness its full potential while contributing to a sustainable bioeconomy."
Journal • Review • Infectious Disease • Novel Coronavirus Disease • Oncology
May 16, 2025
VALIDATION OF A 4-GENE PROGNOSTIC INDEX IN A REAL-WORLD BRAZILIAN COHORT AND EVALUATION OF PHARMACOLOGICAL INHIBITION TO ENHANCE CHEMOTHERAPY RESPONSE IN ACUTE MYELOID LEUKEMIA
(EHA 2025)
- "Aims: Here, we validated the 4-PI in a multicenter Brazilian cohort and investigated whether the pharmacological inhibition of SQLE could sensitize AML cells to cytarabine. Together, our data confirms the prognostic value of 4-PI and SQLE expression in AML. The pharmacological inhibition of SQLE reduced AML cell viability and showed synergistic effects with AraC, supporting the potential repositioning of terbinafine as part of combination therapy for AML treatment."
Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • DHCR7 • FLT3 • IL2RA • SQLE
June 17, 2025
Asymptomatic hepatotoxicity following exposure to oral terbinafine for onychomycosis treatment.
(PubMed, Dermatol Online J)
- "Physician knowledge of this rare but important side effect is necessary to prevent morbidity and mortality resulting from continued therapy. Oral terbinafine therapy might not reactivate hepatitis B in patients with past infection."
Journal • Hepatitis B • Infectious Disease • Inflammation
June 14, 2025
Optimising the detection of Trichophyton indotineae and its prevalence in a large Australian laboratory.
(PubMed, Pathology)
- "indotineae cannot be identified using phenotypic methods, and identification requires ITS sequencing. Whilst apparently uncommon herein, further studies are warranted to more accurately determine the likelihood of encountering this important species in different populations."
Journal • Dermatology • Infectious Disease
June 14, 2025
Aspergillus fumigatus isolated from diverse wildfowl exhibit distinct antifungal susceptibility profiles driven by genetic and non-genetic determinants.
(PubMed, Fungal Genet Biol)
- "Antifungal susceptibility assays against amphotericin B, itraconazole, voriconazole and terbinafine were performed following the Clinical and Laboratory Standards Institute guidelines for filamentous fungi. Notably, single nucleotide polymorphisms (SNPs) were detected across the strains with some correlation between SNPs in antifungal resistance-associated genes and susceptibility profiles; however, antifungal tolerance towards terbinafine was not directly correlated with genetic factors. These data suggest that A. fumigatus isolated from wildfowl with lethal infections from Southern Ontario, Canada, have varying levels of susceptibility to known antifungals and that drivers beyond the anticipated genetic factors influence antifungal response."
Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases
June 13, 2025
Profiling the Tox21 Compound Library for Their Inhibitory Effects on Cytochrome P450 Enzymes.
(PubMed, Int J Mol Sci)
- "Some known structural compound classes exhibiting pan-CYP inhibition, such as azole fungicides, along with established clinical inhibitors of CYPs, including erythromycin and verapamil inhibiting CYP3A4 and paroxetine and terbinafine inhibiting CYP2D6, were all confirmed in the current study. Examples included yohimbine, an indole alkaloid, and loteprednol, a corticosteroid, which showed inhibitory activity in CYP2D6 and 3A4 assays, respectively. These findings suggest that assessment of a candidate compound's impact on CYP function may allow pre-emptive mitigation of potential adverse reactions and toxicity during drug development or toxicological characterization of environmental chemicals."
Journal • CYP3A4
June 10, 2025
Epidemiological and Clinical Profile Analysis of Trichophyton mentagrophytes ITS Genotype VII Infected Dermatomycosis: An Emerging Sexually Transmitted Pathogen.
(PubMed, Mycoses)
- "TMVII can be transmitted through sexual activities, particularly affecting MSM and individuals with concomitant STDs. Current evidence suggests that oral terbinafine is effective, meanwhile other antifungals need further observation. Increased focus is warranted on the clinical management and monitoring of TMVII infection."
Journal • Review • Dermatology • Human Immunodeficiency Virus • Infectious Disease
June 09, 2025
Comparative Analysis of In vitro Susceptibility Profile of Dermatophytes Against 8 Antifungal Agents: A Cross-Sectional Study.
(PubMed, Indian J Dermatol)
- "Antifungal susceptibility test was performed for dermatophytes against eight antifungal agents (terbinafine, griseofulvin, itraconazole, fluconazole, voriconazole, ketoconazole, luliconazole, and posaconazole) using the Clinical and Laboratory Standards Institute broth microdilution method (M38-3rd edition). It was observed that the commonly used antifungals such as fluconazole, griseofulvin, and terbinafine showed high MIC values compared to newer drugs such as luliconazole, posaconazole and voriconazole. More studies based on species distribution and antifungal susceptibility testing (AFST) should be performed to understand the changing epidemiology of dermatophytosis."
Journal • Observational data • Preclinical • Dermatology
June 04, 2025
Unravelling the untapped antifungal potential of polyphenolic compounds by targeting aspartate-beta-semialdehyde dehydrogenase: Insights from multifaceted drug design approaches.
(PubMed, Comput Biol Chem)
- "Furthermore, the toxicity assessment revealed that phytochemicals had a lower chance of causing organ toxicity, whereas terbinafine was more likely to cause respiratory toxicity (0.93) and blood-brain barrier toxicity (0.95). Thus, the present study concludes that keracyanin, cyanidin-3-glucoside, and eriocitrin are promising candidates for the treatment of fungal infections."
Journal • Infectious Disease
1 to 25
Of
958
Go to page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39